peter_george_ceo_clinigen_group

Clinigen chief executive joins Ergomed board

pharmafile | May 28, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Clinigen, ergomed, george 

UK drug development
 services firm Ergomed has appointed Peter George to its
board as a non-executive director.

 

George has over 20 years’ experience in the
industry and is currently chief executive of speciality pharma services firm the Clinigen Group. 

Prior to Clinigen he was chief executive at Penn Pharma, and previously was
executive VP for Wolters Kluwer Health with responsibility for Europe and
Asia-Pacific regions.

Advertisement

George has also held roles as the chief operating
officer of Unilabs Clinical Trials International Limited; head of Clinical
Pathology NHS and as director of PharmaPatents Global.

Chairman of Ergomed Rolf Stahel says: “We are delighted that
Peter has joined Ergomed as non-executive director. He has an excellent
track record of building international pharmaceutical services businesses.”

George adds: “I am very
pleased to join the board of Ergomed. The company has shown strong growth
since its inception 15 years ago and I have been very impressed with the
expertise and quality within the company. I believe Ergomed has great
potential and look forward to being a part of the team.”

Related Content

eusa

EUSA Pharma’s COVID-19 drug improves or stabilises respiratory condition in 76% of patients

EUSA Pharma has unveiled promising preliminary findings from an interim analysis of siltuximab in the …

shutterstock_212432119

EUSA Pharma and Ergomed partner to investigate IL-6 targeting in COVID-19 patients with serious respiratory complications

Oncology and rare disease firm EUSA Pharma is aiding in the global fight against the …

shutterstock_138095450

Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal

Novartis has arranged to sell the remainder of its rights to its skin and lung …

The Gateway to Local Adoption Series

Latest content